Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Cancer tech Patent...

    Cancer tech Patent Infringment: Gilead Sciences told to pay 1.2 billion dollars to Bristol-Myers Squibb

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-04-11T13:56:13+05:30  |  Updated On 11 April 2020 1:56 PM IST
    Cancer tech Patent Infringment: Gilead Sciences told to pay 1.2 billion dollars to Bristol-Myers Squibb

    USA: A federal judge increased to $1.2 billion the damages that Gilead Sciences Inc must pay to Bristol-Myers Squibb Co in a patent infringement case regarding technology for treating cancer.

    The judgment was entered against Gilead's Kite Pharma unit on its "counterclaims of non-infringement and invalidity", according to a ruling by U.S. District Judge Philip Gutierrez.

    The new total of $1.2 billion includes $778 million awarded by a federal jury in December plus enhanced damages of $389 million and pre-judgment interest on the jury's verdict in the amount of $32.8 million, the judge said in his ruling.

    A jury in Los Angeles had awarded damages in December after finding that Yescarta, a treatment sold by Kite Pharma, infringed on a patent exclusively licensed by Bristol-Myers' Juno Therapeutics division.

    The patent at issue in the lawsuit, which Juno licenses from the Memorial Sloan Kettering Cancer Center in New York, relates to CAR T-cell immunotherapy for cancer.

    CAR-T therapy involves a process of removing T cells from a patient's immune system, engineering them to better identify and attack cancer cells and infusing them back into the patient.

    Gilead maintained that Bristol-Myers is not entitled to any level of damages, adding it plans to appeal against the decision.

    "We furthermore strongly believe that the judgment is legally unsupportable and will be reversed," Gilead said in an emailed statement on Thursday.

    "We look forward to addressing these issues on appeal," it added.

    Read also: Bristol Myers Squibb, bluebird bio announce submission of BLA for Myeloma Drug to USFDA

    bristol-myers-squibbgilead-sciencespatent
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok